Preferred Label : SIRP-alpha-Fc Fusion Protein HCB101;
NCIt synonyms : SIRPa-Fc Fusion Protein HCB101;
NCIt definition : A recombinant fusion protein composed of an extracellular domain of human signal-regulatory
protein alpha (SIRP-alpha; SIRPa; CD172a) linked to an Fc domain derived from human
immunoglobulin G4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing
and antineoplastic activities. Upon administration, SIRP-alpha-Fc fusion protein HCB101
selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction
of CD47 with endogenous SIRPa, an inhibitory protein expressed on macrophages and
dendritic cells (DCs), thereby preventing CD47/SIRPa-mediated signaling. This abrogates
the CD47/SIRPa-mediated inhibition of macrophage activation, and induces pro-phagocytic
signaling mediated by the binding of calreticulin (CRT), specifically expressed on
the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein
(LRP), which is expressed on macrophages. This results in macrophage activation and
the specific phagocytosis of tumor cells. Additionally, blocking CD47/SIRPa signaling
activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of
tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated
antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed
on the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells
from phagocytosis, thereby allowing these cells to proliferate and survive.;
Molecule name : HCB-101; HCB 101;
NCI Metathesaurus CUI : CL1928397;
Origin ID : C205788;
concept_is_in_subset
- has_target
